Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

NCT04919642 ↗

Phase 2 Completed 55 enrolled TransThera Sciences (Nanjing), Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

Timeline

Start: 2021-12-07
Primary completion: 2024-02-28
Completion: 2024-02-28

Publications

Javle M, Fountzilas C, Liao CY, Pelster M, Li D, Deming D, Sahai V, Fonkoua LK, Cohn A, Mantry P, Richards D, Kingsley E, Wu F, Peng P, Hennessy K, Wang H, Sun C, Ni S, Fan J, Mahipal A. Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2026 Feb;11(2):137-149. doi: 10.1016/S2468-1253(25)00230-4. Epub 2025 Dec 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tinengotinib	Small molecule	10 mg	Oral

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Summary

Timeline

Publications

Drugs

Indications